Incanthera develops cancer treatment drugs. Its ICT-2588 is a lead compound that is activated within solid tumours by a specific
Incanthera has raised $3.3M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in June 2024.
Incanthera's investors include The North West Fund.
Incanthera is headquartered in Liverpool, United Kingdom.
Incanthera develops cancer treatment drugs. Its ICT-2588 is a lead compound that is activated within solid tumours by a specific
Incanthera is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Incanthera — Funding & Investors." VCBacked, June 3, 2024, https://www.vcbacked.co/company/incanthera. Accessed August 14, 2026.
VCBacked. (2024). Incanthera — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/incanthera
{{cite web |title=Incanthera — Funding & Investors |url=https://www.vcbacked.co/company/incanthera |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated